Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease

Open access
Wilcock, Gordon, Howe, Ian, Coles, Hilary, Lilienfeld, Sean, Truyen, Luc, Zhu, Young, Bullock, Roger · 2003 · Drugs & Aging

Abstract

ObjectiveTo compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer’s disease.Patients and Study DesignThis was a rater-blinded, randomised, parallel-group multicentre study (18 outpatient clinics) in the UK. 182 patients (69 male, 113 female) with Alzheimer’s disease were randomised to galantamine (n = 94) or donepezil (n = 88) for 52 weeks.Main outcome measuresThe effects of galantamine and donepezil on function using the Bristol Activities of Daily Living Scale (BrADL); cognition using the Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog/11); behaviour using the Neuropsychiatric Inventory (NPI); caregiver burden using the Screen for Caregiver Burden; and safety were assessed.ResultsBrADL total scores showed no significant difference between treatment groups in mean change from baseline to week 52. In the total population, in terms of cognition, galantamine patients’ scores on the MMSE at week 52 did not differ significantly from baseline (−0.52 ± 0.39, p < 0.5 vs baseline), whereas donepezil patients’ scores deteriorated significantly from baseline (−1.58 ± 0.42, p < 0.0005 vs baseline). The between-group difference in MMSE change, which showed a trend for superiority of galantamine, did not reach statistical significance (p < 0.1). In the ADAS-cog/11 analysis, between-group differences for the total population were not significant, whereas galantamine-treated patients with MMSE scores of 12–18 demonstrated an increase (worsening) in the ADAS-cog/11 score of 1.61 ± 0.80 versus baseline, compared with an increase of 4.08 ± 0.84 for patients treated with donepezil, with a significant between-group difference in favour of galantamine (p ≤ 0.05). More caregivers of patients receiving galantamine reported reductions in burden compared with donepezil. Changes from baseline in NPI were similar for both treatments.Both treatments were well tolerated; most adverse events were transient and of mild-to-moderate intensity, and were consistent with the findings of previous clinical trials.ConclusionsSignificant advantages were found in the treatment response to galantamine (versus donepezil) on cognition as measured by response rates on the MMSE and ADAS-cog/11.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2165/00002512-200320100-00006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 215

Metadata

Authors
Wilcock, G., Howe, I., Coles, H., Lilienfeld, S., Truyen, L., Zhu, Y., & Bullock, R.
Venue
Drugs & Aging
Published
2003
Volume
20
Issue
10
Pages
777-789
ISSN
1170-229X (ISSN-L)
OpenAlex
W2007050333
Cited by
215
References
6
FWCI
13.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease. https://app.cochat.ai/papers/10.2165/00002512-200320100-00006
The paper
Wilcock, G., Howe, I., Coles, H., Lilienfeld, S., Truyen, L., Zhu, Y., & Bullock, R. (2003). A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease. Drugs & Aging. https://doi.org/10.2165/00002512-200320100-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.